Deal gives Silence exclusive worldwide rights to two siRNA complement assets Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company
Dr. Romano will succeed Dr. Giles Campion, CMO and Head of R&D, following his retirement by year-end Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative
Operator: Good day and thank you for standing by. Welcome to the Silence Therapeutics 2022 Annual Results Conference Call and Webcast. Please be advised that today s conference is being recorded.
Company to host fourth quarter conference call and webcast today at 8 a.m. EDT 12 p.m. GMT Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology